Eli Lilly and Company (NYSE:LLY) Stock Price Up 3.6% – What’s Next?

Eli Lilly and Company (NYSE:LLY) shares traded up 3.6% during trading on Tuesday . The company traded as high as $924.14 and last traded at $918.12. 3,428,457 shares were traded during mid-day trading, an increase of 8% from the average session volume of 3,173,018 shares. The stock had previously closed at $886.63.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly agreed to acquire Centessa Pharmaceuticals for $38/share in an upfront deal (~$6.3B) with potential milestone payments that raise the price to ~ $7.8B — adding OX2R agonists (cleminorexton) that target narcolepsy and other sleep‑wake disorders and immediately expanding Lilly’s neuroscience/sleep portfolio. The acquisition requires regulatory and shareholder approvals. Eli Lilly to buy Centessa Pharma in $6.3 billion deal
• Positive Sentiment: Lilly expanded its AI drug‑discovery partnership with Insilico Medicine in a deal potentially worth up to $2.75B, giving Lilly exclusive commercialization rights to AI‑discovered candidates — a strategic move to accelerate R&D, lower discovery timelines and broaden future product flow. Eli Lilly extends partnership with Insilico Medicine for AI-powered drug discovery
• Positive Sentiment: Recent earnings and guidance show strong cash flow and high margins (recent quarter beat and FY guidance raised), supporting Lilly’s ability to fund M&A and large R&D investments without straining the balance sheet. This underpins investor confidence in funding the Centessa buy and AI deals. Eli Lilly and Company financial snapshot
• Neutral Sentiment: Analyst activity remains constructive: Jefferies reiterated a Buy and some firms maintain upside targets, while others made minor price‑target tweaks — signaling continued bullish institutional view but varied near‑term valuations. Jefferies Remains a Buy on Eli Lilly
• Neutral Sentiment: Industry/partner signaling: a former Lilly executive was nominated to Lonza’s board — a peripheral personnel development that may help industry relationships but is unlikely to move LLY shares materially. Lonza strengthens board with nomination of former Eli Lilly executive
• Negative Sentiment: Lilly is pressing for higher NHS pricing and changes to U.K. rebate rules to restart investment there — a negotiation that could provoke political/payer pushback and introduce reimbursement risk in an important market. Eli Lilly seeks higher NHS drug prices, rebate overhaul

Analysts Set New Price Targets

Several research firms recently weighed in on LLY. Bank of America decreased their target price on Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating for the company in a research note on Monday, December 15th. Royal Bank Of Canada began coverage on shares of Eli Lilly and Company in a research note on Tuesday, February 24th. They issued an “outperform” rating and a $1,250.00 price target on the stock. Berenberg Bank raised their price objective on shares of Eli Lilly and Company from $950.00 to $1,050.00 and gave the stock a “hold” rating in a report on Thursday, February 19th. Jefferies Financial Group set a $1,300.00 price objective on shares of Eli Lilly and Company and gave the stock a “buy” rating in a research report on Friday, March 13th. Finally, Weiss Ratings restated a “buy (b)” rating on shares of Eli Lilly and Company in a report on Friday. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average target price of $1,221.26.

Eli Lilly and Company Trading Up 3.6%

The business has a 50-day moving average of $1,004.20 and a 200-day moving average of $965.80. The stock has a market capitalization of $867.46 billion, a price-to-earnings ratio of 40.01, a PEG ratio of 1.02 and a beta of 0.40. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, topping the consensus estimate of $7.48 by $0.06. The company had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The firm’s revenue was up 42.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Institutional Trading of Eli Lilly and Company

Several institutional investors and hedge funds have recently bought and sold shares of the business. Brighton Jones LLC grew its holdings in shares of Eli Lilly and Company by 22.0% during the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after buying an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC lifted its position in Eli Lilly and Company by 2.8% during the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after acquiring an additional 40 shares during the period. Schnieders Capital Management LLC. lifted its position in Eli Lilly and Company by 16.7% during the 2nd quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock worth $6,231,000 after acquiring an additional 1,141 shares during the period. Proactive Wealth Strategies LLC grew its stake in shares of Eli Lilly and Company by 5.6% in the 2nd quarter. Proactive Wealth Strategies LLC now owns 1,398 shares of the company’s stock valued at $1,090,000 after purchasing an additional 74 shares during the last quarter. Finally, Virtus Advisers LLC acquired a new position in shares of Eli Lilly and Company in the second quarter valued at approximately $179,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.